Diagonal Therapeutics develops agonist antibodies to treat rare cardiovascular conditions. Using artificial intelligence, the startup’s technology sorts through billions of antibody/receptor combinations to identify the ones that reactivate signaling pathways lost to disease.
The post Diagonal Therapeutics’ New Slant Attracts $128M to Reactivate Antibody Drug R&D appeared first on MedCity News.
